NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: D
Post# of 188
(Total Views: 281)
Posted On: 03/02/2021 3:17:14 PM
NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Results of New Clinical Study Showing Value of Personalization
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled “Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study,” which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth’s digital health platform. The study focused on demonstrating the effect of digital engagement on improving monthly average blood glucose levels during a patient’s first year of managing their diabetes on the platform. The study noted that highly engaged users who maintained consistent digital engagement with the platform demonstrated statistically significant improvement during the initial period relative to engaged users, 13% vs. 9% respectively. The study also noted a 43% decrease in monthly average glucose levels in the month following increased digital engagement from the month prior, during the initial six-month period. “A key goal at DarioHealth is to solve for the shortcomings of first-generation digital health solutions,” said DarioHealth chief medical officer Dr. Omar Manejwala in the press release. “These platforms have made major strides, but we believe that they are missing key ingredients — including the marriage of behavioral science with AI — which is why many solutions haven’t seen a lot of meaningful and sustained engagement to date. DarioHealth’s direct-to-consumer (“D2C”) experience offers a unique opportunity to examine longitudinal consumer data through studies like this and to analyze how behaviors change over time. DarioHealth is focused on becoming a digital center of excellence that provides a complete virtual care solution to support behavior changes that improve chronic conditions through our next-generation personalization technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled “Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study,” which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth’s digital health platform. The study focused on demonstrating the effect of digital engagement on improving monthly average blood glucose levels during a patient’s first year of managing their diabetes on the platform. The study noted that highly engaged users who maintained consistent digital engagement with the platform demonstrated statistically significant improvement during the initial period relative to engaged users, 13% vs. 9% respectively. The study also noted a 43% decrease in monthly average glucose levels in the month following increased digital engagement from the month prior, during the initial six-month period. “A key goal at DarioHealth is to solve for the shortcomings of first-generation digital health solutions,” said DarioHealth chief medical officer Dr. Omar Manejwala in the press release. “These platforms have made major strides, but we believe that they are missing key ingredients — including the marriage of behavioral science with AI — which is why many solutions haven’t seen a lot of meaningful and sustained engagement to date. DarioHealth’s direct-to-consumer (“D2C”) experience offers a unique opportunity to examine longitudinal consumer data through studies like this and to analyze how behaviors change over time. DarioHealth is focused on becoming a digital center of excellence that provides a complete virtual care solution to support behavior changes that improve chronic conditions through our next-generation personalization technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)DarioHealth Corp. (DRIO) Stock Research Links
Scroll down for more posts ▼